MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ge, Yu Zheng ^a   Xin, Hui ^a   Lu, Tian Ze ^a   Xu, Zheng ^a   Yu, Peng ^b   Zhao, You Cai ^a   Li, Ming Hao ^a   Zhao, Yan ^c   Zhong, Bing ^d   Xu, Xiao ^e   Zhou, Liu Hua ^a   Wu, Ran ^a   Xu, Lu Wei ^a   Wu, Jian Ping ^a   Li, Wen Cheng ^a   Zhu, Jia Geng ^a   Jia, Rui Peng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

^c JIANGSU UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e Nanjing Branch Jiangsu Armed Police General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; TRANSCRIPTOME; TUMOR BURDEN;

EID: 84929431384     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10328     Document Type: Article

References (38)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90, doi:10.3322/caac.20107 (2011).
2. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29, doi:10.3322/caac.21208 (2014).
3. Zhao, P. J. et al. Chromophobe renal cell carcinoma: analysis of 53 cases. J. Cancer Res. Clin. Oncol. 138, 451-454, doi:10.1007/s00432-011-1112-z (2012).
4. Pai, A., Brunson, A., Brown, M., Pan, C. X. & Lara, P. N., Jr. Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry. Urology 82, 840-845, doi:10.1016/j.urology.2013.07.020 (2013).
5. Linehan, W. M. & Rathmell, W. K. Kidney cancer. Urol Oncol. 30, 948-951, doi:10.1016/j.urolonc.2012.08.021 (2012).
6. Klatte, T. et al. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 26, 604-609, doi:10.1016/j.urolonc.2007.07.015 (2008).
7. Volpe, A. et al. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 110, 76-83, doi:10.1111/j.1464-410X.2011.10690.x (2012).
8. Tilki, D. et al. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. Eur. Urol., doi:10.1016/j.eururo.2013.06.048 (2013).
9. Lewis, B. P., Burge, C. B. & Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120, 15-20, doi:10.1016/j.cell.2004.12.035 (2005).
10. Yates, L. A., Norbury, C. J. & Gilbert, R. J. The long and short of microRNA. Cell. 153, 516-519, doi:10.1016/j.cell.2013.04.003 (2013).
11. Jansson, M. D. & Lund, A. H. MicroRNA and cancer. Mol. Oncol. 6, 590-610, doi:10.1016/j.molonc.2012.09.006 (Differentially expressed miRNAs in chRCC vs. adjacent normal tissue).
12. Maher, E. R. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol. 23, 10-17, doi:10.1016/j.semcancer.2012.06.003 (2013).
13. Huang, C. T., Oyang, Y. J., Huang, H. C. & Juan, H. F. MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma. Sci. Rep. 4, 6495, doi:10.1038/srep06495 (2014).
14. Fujita, Y., Kuwano, K., Ochiya, T. & Takeshita, F. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research. Biomed Res Int 2014, 486413, doi:10.1155/2014/486413 (2014).
15. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866, doi:10.1038/nrc1997 (2006).
16. Juan, L. et al. Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients. Sci. Rep. 4, 6277, doi:10.1038/srep06277 (2014).
17. Juan, D. et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 75, 835-841, doi:10.1016/j.urology.2009.10.033 (2010).
18. Osanto, S. et al. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One 7, e38298, doi:10.1371/journal.pone.0038298 (2012).
19. Wu, X. et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7, e35661, doi:10.1371/journal.pone.0035661 (2012).
20. Youssef, Y. M. et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol. 59, 721-730, doi:10.1016/j.eururo.2011.01.004 (2011).
21. Silva-Santos, R. M. et al. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br. J. Cancer 109, 2646-2653, doi:10.1038/bjc.2013.552 (2013).
22. Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319-330, doi:10.1016/j. ccr.2014.07.014 (2014).
23. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
24. Selbach, M. et al. Widespread changes in protein synthesis induced by microRNAs. Nature 455, 58-63, doi:10.1038/nature07228 (2008).
25. Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64-71, doi:10.1038/nature07242 (2008).
26. Sandoval, J. & Esteller, M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22, 50-55, doi:10.1016/j.gde.2012.02.008 (2012).
27. Iorio, M. V. & Croce, C. M. microRNA involvement in human cancer. Carcinogenesis 33, 1126-1133, doi:10.1093/carcin/bgs140 (2012).
28. Liu, X. et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J. Exp. Clin. Cancer Res. 32, 96, doi:10.1186/1756-9966-32-96 (2013).
29. Gowrishankar, B. et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol. Ther. 15, 329-341, doi:10.4161/cbt.27314 (2014).
30. Li, R. et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J. Exp. Clin. Cancer Res. 33, 9, doi:10.1186/1756-9966-33-9 (2014).
31. Nakada, C. et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 216, 418-427, doi:10.1002/path.2437 (2008).
32. Ivan, M. & Huang, X. miR-210: fine-tuning the hypoxic response. Adv. Exp. Med. Biol. 772, 205-227, doi:10.1007/978-1-4614-5915-6-10 (2014).
33. Hong, L., Han, Y., Zhang, H., Zhao, Q. & Qiao, Y. miR-210: a therapeutic target in cancer. Expert Opin. Ther. Targets 17, 21-28, doi:10.1517/14728222.2012.732066 (2013).
34. Qin, Q., Furong, W. & Baosheng, L. Multiple functions of hypoxia-regulated miR-210 in cancer. J. Exp. Clin. Cancer Res. 33, 50, doi:10.1186/1756-9966-33-50 (2014).
35. Iwamoto, H. et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int. J. Oncol. 44, 53-58, doi:10.3892/ijo.2013.2169 (2014).
36. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68-73, doi:10.1093/nar/gkt1181 (2014).
37. Jemal, A. et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J. Natl. Cancer Inst. 105, 175-201, doi:10.1093/jnci/djs491 (2013).
38. Qi, Q., Zhao, Y., Li, M. & Simon, R. Non-negative matrix factorization of gene expression profiles: a plug-in for BRB-ArrayTools. Bioinformatics 25, 545-547, doi:10.1093/bioinformatics/btp009 (2009).